These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 34920919)

  • 1. Repeated detrusor injection of botulinum toxin A for neurogenic bladder in children: A long term option?
    Madec FX; Suply E; Forin V; Chamond O; Lalanne A; Irtan S; Audry G; Lallemant P
    Prog Urol; 2022 Apr; 32(5):319-325. PubMed ID: 34920919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Intradetrusor injections of botulinum toxin A to treat urinary incontinence due to bladder overactivity during idiopathic Parkinson's disease].
    Atamian A; Sichez PC; Michel F; Bandelier Q; Fall M; Gaillet S; Azoulay JP; Lechevallier E; Karsenty G
    Prog Urol; 2021 Jun; 31(7):430-438. PubMed ID: 33579624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from onabotulinum toxin A to abobotulinum toxin A for treating detrusor overactivity in spinal cord injured patient, does it really work?
    Le Roy C; Lefèvre C; Lepoittevin L; Reiss B; Le Fort M; Rigaud J; Perrouin-Verbe B; Perrouin-Verbe MA
    Prog Urol; 2023 Sep; 33(10):503-508. PubMed ID: 37550178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed.
    Bottet F; Peyronnet B; Boissier R; Reiss B; Previnaire JG; Manunta A; Kerdraon J; Ruffion A; Lenormand L; Perrouin Verbe B; Gaillet S; Gamé X; Karsenty G;
    Neurourol Urodyn; 2018 Jan; 37(1):291-297. PubMed ID: 28431196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urodynamic Outcomes in Children after Single and Multiple Injections for Overactive and Low Compliance Neurogenic Bladder Treated with Abobotulinum Toxin A.
    Naqvi S; Clothier J; Wright A; Garriboli M
    J Urol; 2020 Feb; 203(2):413-419. PubMed ID: 31518199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity.
    Veeratterapillay R; Harding C; Teo L; Vasdev N; Abroaf A; Dorkin TJ; Pickard RS; Hasan T; Thorpe AC
    Int J Urol; 2014 Feb; 21(2):175-8. PubMed ID: 23819724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Definition of botulinum toxin failure in neurogenic detrusor overactivity: Preliminary results of the DETOX survey].
    Peyronnet B; Sanson S; Amarenco G; Castel-Lacanal E; Chartier-Kastler E; Charvier K; Damphousse M; Denys P; de Seze M; Egon G; Even A; Forin V; Karsenty G; Kerdraon J; le Normand L; Loche CM; Manunta A; Mouracade P; Phe V; Previnaire JG; Ruffion A; Saussine C; Schurch B; Game X;
    Prog Urol; 2015 Dec; 25(17):1219-24. PubMed ID: 26318394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Discontinuation of Botulinum Toxin A Intradetrusor Injections for Neurogenic Detrusor Overactivity: A Multicenter Study.
    Baron M; Peyronnet B; Aublé A; Hascoet J; Castel-Lacanal E; Miget G; Le Doze S; Prudhomme T; Manunta A; Cornu JN; Gamé X
    J Urol; 2019 Apr; 201(4):769-776. PubMed ID: 30359679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum injection is useless on fibrotic neuropathic bladders.
    Tiryaki S; Yagmur I; Parlar Y; Ozel K; Akyildiz C; Avanoglu A; Ulman I
    J Pediatr Urol; 2015 Feb; 11(1):27.e1-4. PubMed ID: 25448589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity.
    Karsenty G; Reitz A; Lindemann G; Boy S; Schurch B
    Urology; 2006 Dec; 68(6):1193-7. PubMed ID: 17141831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intradetrusor onabotulinum-a toxin injections in children with therapy-resistant idiopathic detrusor overactivity. A retrospective study.
    Ringoir A; Dhondt B; De Bleser E; Van Laecke E; Everaert K; Groen LA; Hoebeke P; Spinoit AF
    J Pediatr Urol; 2020 Apr; 16(2):181.e1-181.e8. PubMed ID: 31964616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin type A injection for neurogenic detrusor overactivity: clinical outcome in Japanese patients.
    Hikita K; Honda M; Kawamoto B; Panagiota T; Inoue S; Hinata N; Muraoka K; Takenaka A
    Int J Urol; 2013 Jan; 20(1):94-9. PubMed ID: 23126535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Injections of Botulinum Toxin A into the detrusor to treat neurogenic detrusor overactivity secondary to spinal cord injury.
    Chen G; Liao L
    Int Urol Nephrol; 2011 Sep; 43(3):655-62. PubMed ID: 21110094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of electromotive drug administration in delivering botulinum toxin a in children with neuropathic detrusor overactivity-outcomes of a pilot study.
    Koh C; Melling CV; Jennings C; Lewis M; Goyal A
    J Pediatr Urol; 2019 Oct; 15(5):552.e1-552.e8. PubMed ID: 31326328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity.
    Gamé X; Khan S; Panicker JN; Kalsi V; Dalton C; Elneil S; Hamid R; Dasgupta P; Fowler CJ
    BJU Int; 2011 Jun; 107(11):1786-92. PubMed ID: 21040367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin injections in the management of non-neurogenic overactive bladders in children.
    Léon P; Jolly C; Binet A; Fiquet C; Vilette C; Lefebvre F; Bouché-Pillon-Persyn MA; Poli-Mérol ML
    J Pediatr Surg; 2014 Sep; 49(9):1424-8. PubMed ID: 25148752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment.
    Alloussi SH; Lang Ch; Eichel R; Al-Kaabneh A; Seibold J; Schwentner C; Alloussi S
    World J Urol; 2012 Jun; 30(3):367-73. PubMed ID: 21842216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of Urinary Brain-Derived Neurotrophic Factor Levels on the Assessment of Botulinum Toxin Type A Treatment for Neurogenic Detrusor Overactivity in Children with Myelodysplasia.
    Sekerci CA; Tanidir Y; Toprak T; Basok BI; Isman F; Simsek F; Akbal C; Tarcan T
    J Urol; 2019 Jan; 201(1):174-180. PubMed ID: 30577408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin for the management of bladder dysfunction.
    Schurch B
    Drugs; 2006; 66(10):1301-18. PubMed ID: 16903766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term compliance and results of intravesical botulinum toxin A injections in male patients.
    Rahnama'i MS; Marcelissen TAT; Brierley B; Schurch B; de Vries P
    Neurourol Urodyn; 2017 Sep; 36(7):1855-1859. PubMed ID: 28084637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.